Wagner Jeffrey D, Evdokimow David Z, Weisberger Edward, Moore David, Chuang Tsu-Yi, Wenck Stacie, Coleman John J
Division of Plastic Surgery, Department of Surgery, Indiana University School of Medicine, Indianapolis, USA.
Arch Dermatol. 2004 Jan;140(1):75-9. doi: 10.1001/archderm.140.1.75.
To evaluate the feasibility of sentinel node staging for detection of occult regional lymph node metastasis in high-risk cutaneous nonmelanoma malignancies.
Consecutive clinical case series.
Referral university medical center.
A consecutive sample of patients with a variety of high-risk nonmelanoma cutaneous malignancies without evidence of regional lymph node metastases.
Sentinel node biopsies were performed using preoperative lymphoscintigraphy, blue dye, and intraoperative radiolocalization.
Sensitivity, determined by comparing the results of biopsy specimen evaluation with those of completion lymphadenectomy and/or clinical follow-up.
Twenty-four patients underwent sentinel node biopsy for the staging of 29 nodal basins identified by lymphoscintigraphy. Primary diagnoses were squamous cell carcinoma (n = 17), Merkel cell carcinoma (n = 5), and adenocarcinoma (n = 2). Seven patients (29%) had a tumor-positive sentinel node. Sentinel node biopsy followed by complete lymphadenectomy was performed in 12 patients and sentinel node biopsy alone in 12 patients. Tumor-positive lymph nodes were noted in 8 patients, 7 of whom also had positive sentinel nodes. There was 1 false-positive result (1/8 [12%]), in a patient with recurrent squamous cell carcinoma of the scalp. At a median follow-up of 10 months, no recurrences in a sentinel node-negative basin have been noted. Compared with all information, the sensitivity of sentinel node staging was 88% and the negative predictive value was 0.94.
Sentinel node biopsy is a minimally invasive staging procedure useful in identifying occult regional lymph node disease in selected patients with nonmelanoma cutaneous malignancies. Further studies to verify these findings and develop formal guidelines are indicated.
评估前哨淋巴结分期用于检测高危皮肤非黑色素瘤恶性肿瘤隐匿性区域淋巴结转移的可行性。
连续临床病例系列。
转诊大学医学中心。
连续选取的患有多种高危非黑色素瘤皮肤恶性肿瘤且无区域淋巴结转移证据的患者样本。
采用术前淋巴闪烁显像、蓝色染料和术中放射性定位进行前哨淋巴结活检。
通过将活检标本评估结果与根治性淋巴结清扫术和/或临床随访结果进行比较来确定敏感性。
24例患者接受了前哨淋巴结活检,以对淋巴闪烁显像确定的29个淋巴结区域进行分期。主要诊断为鳞状细胞癌(n = 17)、默克尔细胞癌(n = 5)和腺癌(n = 2)。7例患者(29%)前哨淋巴结肿瘤阳性。12例患者在进行前哨淋巴结活检后接受了根治性淋巴结清扫术,12例患者仅接受了前哨淋巴结活检。8例患者发现肿瘤阳性淋巴结,其中7例前哨淋巴结也为阳性。1例头皮复发性鳞状细胞癌患者出现1例假阳性结果(1/8 [12%])。中位随访10个月时,前哨淋巴结阴性区域未发现复发。与所有信息相比,前哨淋巴结分期的敏感性为88%,阴性预测值为0.94。
前哨淋巴结活检是一种微创分期方法,有助于识别特定的非黑色素瘤皮肤恶性肿瘤患者的隐匿性区域淋巴结疾病。需要进一步研究以验证这些发现并制定正式指南。